Rezolve-AD Study Insights
At the 2026 American Academy of Dermatology (AAD) Annual Meeting, held in Denver, Colorado, Nektar Therapeutics shared pivotal data from its global Phase
2b Rezolve-AD trial. This extensive study involved 393 participants grappling with moderate-to-severe atopic dermatitis. Patient entry into the trial was carefully managed, with randomization strategies in place to account for differences in baseline disease severity, assessed via the vIGA-AD scale, and their geographical origins. The presented findings indicated a consistent and notable decrease in mean Eczema Area and Severity Index (EASI) scores throughout the 16-week induction phase for patients receiving the investigational treatment when compared to those on a placebo. Crucially, this improvement was observed irrespective of the initial severity of their condition, as determined by vIGA-AD scores of 3 or 4. Furthermore, the study reported that patients achieved comparable rates of EASI-75 and EASI-90 responses, signifying substantial improvements in skin condition. These positive outcomes related to disease control were also consistent across different geographical regions where the study was conducted, underscoring the potential broad applicability of the therapeutic approach.
